Journal article
Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease
- Abstract:
-
Aims
REVEAL was the first randomized controlled trial to demonstrate that adding cholesteryl ester transfer protein inhibitor therapy to intensive statin therapy reduced the risk of major coronary events. We now report results from extended follow-up beyond the scheduled study treatment period.Methods and results
A total of 30 449 adults with prior atherosclerotic vascular disease were randomly allocated to anacetrapib 100 mg daily or matching... Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 811.9KB, Terms of use)
-
- Publisher copy:
- 10.1093/eurheartj/ehab863
Funding
Bibliographic Details
- Publisher:
- Oxford University Press
- Journal:
- European Heart Journal More from this journal
- Volume:
- 43
- Issue:
- 14
- Pages:
- 1416-1424
- Place of publication:
- England
- Publication date:
- 2021-12-15
- Acceptance date:
- 2021-12-02
- DOI:
- EISSN:
-
1522-9645
- ISSN:
-
0195-668X
- Pmid:
-
34910136
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1225688
- Local pid:
-
pubs:1225688
- Deposit date:
-
2022-09-28
Terms of use
- Copyright holder:
- Sammons et al.
- Copyright date:
- 2022
- Rights statement:
- © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record